ArticlePatient preference and adherence2026
iPREFER: Patients' Experiences and Preference of Treatment for Multiple Myeloma Following Multiple Lines of Treatment - A Qualitative Study.
Article in Patient preference and adherence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06322927 (PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Each year in the United Kingdom, approximately 6000 people are diagnosed with Multiple Myeloma (MM) and treated with targeted cancer drugs. The duration and frequency of these treatments vary and include oral, intravenous (IV), and subcutaneous administration. Patients often undergo multiple lines of treatment and live with uncertainty spanning years and decades. This study (ClinicalTrials.gov Identifier: NCT06322927) explores the experiences of people receiving treatment for MM, what matters most when making treatment decisions, and what influences their treatment preference. Patients and Methods: This was a qualitative study using semi-structured interviews. Patients were eligible if they had a confirmed MM diagnosis and received at least five lines of treatment. Interviews focused on their extensive experiences of multiple lines of oral anti-cancer and bispecific antibody treatment, or IV therapy, and were analyzed using inductive thematic analysis. Results: Four key themes were identified from nine interviews: "Living with MM and its impact on quality of life", portrays the relentless challenges and side effects of MM; "Factors influencing treatment decision making" outlines the importance of family, shared decision-making and information needs; "Factors influencing treatment experience", including practical challenges, and self-management; and "Treatment preference" explores participants' perceptions of treatment within the context of their own circumstances. Participants showed a willingness and tolerance to accept treatments that significantly impact their everyday life, quality of life, and relationships, to achieve their goals of care. Conclusion: The findings highlight the need for healthcare professionals to better understand individual patient circumstances and priorities, inform them of the treatment impact on their priorities to empower patients to choose the right treatment for them and improve quality of life. More research is needed to understand how to integrate this into the clinical care pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.